Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Endocrine 2

Conditions

Thyroid Neoplasms 1Familial medullary thyroid carcinoma 1Differentiated Thyroid Cancer 1Carcinoma, Medullary 1

Interventions

Everolimus 8lanreotide 7Octreotide 7lutetium Lu 177 dotatate 6pasireotide 5Thyrotropin Alfa 5Mitotane 4Etoposide 4Doxorubicin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Mifepristone 3Filgrastim 3Corlux 3Cisplatin 3Chemotherapy, Adjuvant 3Capecitabine 3Cabergoline 3vandetanib 2telotristat ethyl 2surufatinib 2ribociclib 2fluorodopa F 18 2cabozantinib 2Temozolomide 2Receptor-Like Protein Tyrosine Phosphatases, Class 2 2Lutetium-177 2Lutetium 2Leucovorin 2Iodine-131 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × vandetanib × Endocrine × Clear all
NCT00410761 2025-09-24

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Sanofi

Phase 3 Completed
331 enrolled 15 charts
EndocrineHead & Neck

Familial medullary thyroid carcinoma, Thyroid Neoplasms, Carcinoma, Medullary

NCT01876784 2024-07-23

VERIFY

Sanofi

Phase 3 Completed
238 enrolled 12 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡